INVERNESS COUNSEL LLC /NY/ - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 62 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
INVERNESS COUNSEL LLC /NY/ ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$299,000
-52.3%
1,210,5370.0%0.02%
-51.4%
Q2 2022$627,000
-74.7%
1,210,5370.0%0.04%
-68.5%
Q1 2022$2,482,000
-50.8%
1,210,5370.0%0.11%
-40.3%
Q4 2021$5,048,000
+3874.8%
1,210,537
+8786.6%
0.19%
+3620.0%
Q3 2021$127,000
-47.1%
13,622
+2.4%
0.01%
-44.4%
Q2 2021$240,00013,3070.01%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders